Researchers at the Department of Pharmacognosy, The School of Pharmacy, University of London, UK, basis the study conducted on mice found that CBD oil has analgesic properties and may relieve chronic pain of all kinds . It can disrupt the activity of pain receptors in the body and instead cause a release of neurotransmitters such as serotonin and dopamine – “feel good” compounds that can ease discomfort and pain, even if the pharmaceutical painkillers have no effect.
There are likely very complex relationships also occurring between various Cannabinoids in Cannabis that may lead to certain medical efficacy. That is important to remember when considering the consumption of products that contain Cannabinoids. There is an attractiveness to isolating a specific chemical, researching it, patenting synthetic derivatives, and marketing specific drugs. That said, the relationships are complex, will likely take years to understand, and many patients I’ve met appear to find the most medical benefit from a diverse group of Cannabinoids whose interactions are not particularly well understand, but the results are hard to argue with.
At this time, there does seem to be a growing body of basic pharmacologic data suggesting there may be a role for CBD, especially in the treatment of refractory epilepsy. However, given the lack of well-controlled trials, we must also ask if we are getting ahead of ourselves. Clearly, this is an emotionally and politically charged issue. If this were any other uninvestigated pharmaceutical compound, would we feel as compelled to make the agent widely available before statistically valid class 1 evidence was available for review? Until data from well-designed clinical trials are available and reliable, and standardized CBD products that are produced using GMP are available, caution must be exercised in any consideration of using CBD for the treatment of epilepsy. In the meantime, based upon promising preliminary data, further clinical research should be wholeheartedly pursued.

Transparency: cbdMD seems to be going through a transition with their third-party testing practices. Until recently, they only released a lab report for the CBD concentrate they use for all their products, but would not show potency testing for individual products. That seems to be changing. Currently, the only lab report on the website is for their concentrate (and it’s over a year old). But if you contact customer service, they’ll send you a lab report for any product. 


Cannabis has always been a popular form of treatment for a variety of medical conditions, but in the 1930’s growing concerns about the dangers of marijuana abuse led to cannabinoids being banned. A century has past and despite all efforts from cannabis enthusiasts through social media channels and online media, cannabis is still classed as a schedule 1 drug.

×